Sangamo Therapeutics Inc (OQ:SGMO)

Mar 22, 2024 08:05 am ET
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has entered into a securities purchase agreement with institutional investors, providing for the purchase and sale of an aggregate of 24,761,905 shares of its common stock and pre-funded warrants to purchase up to an aggregate of 3,809,523 shares of common stock, together with accompanying warrants to purchase up to an aggregate of 28,571,428 shares of common stock. The combined offering price of each share of common stock and accompanying warrant is $0.84, priced at-the-market under Nasdaq rules. Th
Mar 13, 2024 08:05 am ET
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2023 financial results, including meaningful data to support advancement of its neurology pipeline.
Mar 13, 2024 08:01 am ET
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced preclinical data from its proprietary adeno-associated virus (AAV) capsid variant, STAC-BBB, that demonstrated robust penetration of the blood-brain barrier (BBB) and strong transgene expression throughout the central nervous system (CNS) of NHPs when administered intravenously at clinically-relevant doses, outperforming results obtained by Sangamo for other known neurotropic capsid variants evaluated in the study. Importantly, potent repression of target genes was observed in brain cells expressing the zinc
Mar 12, 2024 06:30 pm ET
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its fourth quarter and full year 2023 financial results before the market opens on Wednesday, March 13, 2024.
Feb 12, 2024 08:05 am ET
Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced important U.S. and European regulatory updates for isaralgagene civaparvovec, or ST-920, its wholly owned gene therapy product candidate for the treatment of Fabry disease.
Feb 05, 2024 06:01 pm ET
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary data from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease. In the largest known clinical gene therapy program in Fabry disease to date, data from 24 patients continued to show durable safety and preliminary efficacy data as of the data cutoff date, which continue to underscore the potential of isaralgagene civaparvovec as a single-dose treatment option for Fabry disease.
Nov 01, 2023 04:01 pm ET
Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced recent business highlights, including progress on its strategic transformation and a corresponding restructuring of operations and workforce reduction, and reported third quarter 2023 financial results.
Oct 25, 2023 04:15 pm ET
Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its third quarter 2023 financial results after the market closes on Wednesday, November 1, 2023.
Oct 24, 2023 02:01 am ET
Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (E
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the European Society of Gene & Cell Therapy (ESGCT) has accepted six Sangamo abstracts for presentation at the 30th Annual Congress being held October 24-27, 2023, in-person in Brussels, Belgium. Presentations will focus on the progression of Sangamo’s pre-clinical programs, including data from its neurology epigenetic regulation programs, and advancements in the CAR-Treg pipeline.
Sep 20, 2023 04:15 pm ET
Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that it will participate in the Jefferies Cell & Genetic Medicine Summit, to be held from September 26-27, 2023 in New York City.
Aug 08, 2023 04:01 pm ET
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and second quarter 2023 financial results.
Aug 01, 2023 04:15 pm ET
Sangamo Therapeutics Announces Second Quarter 2023 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its second quarter 2023 financial results after the market closes on Tuesday, August 8, 2023.
Jul 20, 2023 08:05 am ET
Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a clinical-stage genomic medicine company and Chroma Medicine, Inc. (Chroma), a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced they have entered into a research evaluation, option and license agreement to develop epigenetic medicines leveraging zinc finger proteins (ZFPs) for sequence-specific DNA recognition. Over the course of two decades, Sangamo has built and validated the world’s largest library of ZFPs, deploying them to address numerous therapeutically relevant targets. Advancing the transformat
Jul 17, 2023 08:05 am ET
Sangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered Capsids
Sangamo Therapeutics, Inc. (“Sangamo”, Nasdaq: SGMO), a genomic medicine company, today announced it has signed an evaluation and option agreement with Prevail Therapeutics (“Prevail”), a wholly owned subsidiary of Eli Lilly and Company, through which Prevail has been granted rights to evaluate certain proprietary adeno-associated virus (AAV) capsids developed by Sangamo and may exercise certain options to license these capsids for multiple undisclosed neurological targets. Generated through Sangamo’s AAV capsid engineering platform, SIFTER (Selecting In vivo For Transduction and Expression of
Jun 29, 2023 08:05 am ET
Sangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, and Voyager Therapeutics, Inc. (Nasdaq: VYGR), today announced the parties have entered into a definitive license agreement for a potential treatment of prion disease. Using its proprietary epigenetic regulation platform, Sangamo has developed zinc finger transcriptional regulators (ZF-TRs) which it believes can specifically and potently block expression of the prion protein, the pathogenic driver of prion disease. Sangamo’s ZF-TRs have been shown in animal models to significantly reduce expression of the prion protein in t
May 22, 2023 08:05 am ET
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for Isaralgagene Civaparvovec for the Treatment of Fabry Disease
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease.
May 16, 2023 08:00 am ET
Sangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer. She will serve on the Executive Leadership team and report to Nathalie Dubois-Stringfellow, Sangamo’s Chief Development Officer. Dr Rojkjaer succeeds Bettina Cockroft, M.D., M.B.A, who is leaving the company to pursue other opportunities. We thank her for her contributions.
May 02, 2023 04:30 pm ET
Sangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted 14 Sangamo abstracts for presentation at the 26th ASGCT Annual Meeting being held May 16-20, 2023, in-person in Los Angeles, CA and in a virtual format. Presentations will focus on the progression of Sangamo’s pre-clinical programs, including data from the prioritized neurology programs Nav1.7 and Prion, innovations in the epigenetic regulation platform and advances in AAV capsid engineering for delivery.
Apr 26, 2023 05:28 pm ET
Sangamo Therapeutics Announces Strategic Update and Reports Preliminary First Quarter 2023 Financial Results
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced recent business highlights, including a strategic pipeline prioritization and restructuring, and reported certain preliminary first quarter 2023 financial results.
Apr 19, 2023 04:15 pm ET
Sangamo Therapeutics Announces First Quarter 2023 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company is scheduled to release its first quarter 2023 financial results after the market closes on Wednesday, April 26, 2023.
Feb 27, 2023 07:30 am ET
Thinking about buying stock in Broadmark Realty Capital, Seagen, Sangamo Therapeutics, Li Auto, or Bed Bath & Beyond?
NEW YORK, Feb. 27, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BRMK, SGEN, SGMO, LI, and BBBY.
Feb 22, 2023 04:01 pm ET
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2022 financial results.
Feb 22, 2023 03:01 pm ET
Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary data as of the October 20, 2022 cutoff date from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease. These data, which present new biomarker data and results from the first kidney biopsies in this study, indicate evidence of clinical benefit for isaralgagene civaparvovec in Fabry disease.
Feb 21, 2023 09:01 am ET
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company is scheduled to hold a conference call on Wednesday, February 22, 2023 at 4:30 p.m. ET to review its fourth quarter and full year 2022 financial results and business updates. Prior to the call, the company will have released its fourth quarter and full year financial results.
Nov 03, 2022 04:01 pm ET
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and third quarter 2022 financial results.
Oct 27, 2022 04:15 pm ET
Sangamo Therapeutics Announces Third Quarter 2022 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company is scheduled to release its third quarter 2022 financial results after the market closes on Thursday, November 3, 2022.
Oct 12, 2022 03:01 am ET
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Nine Patients
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary results from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease. These latest data show that, as of the July 21, 2022 cutoff date, the investigational treatment continued to be generally well tolerated, with no treatment-related serious adverse events. The nine patients in the dose escalation phase exhibited elevated alpha-galactosidase A (α-Gal A) activity, sustained for up t
Aug 30, 2022 06:00 am ET
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated α-gal A Enzyme Activity in Five Longest Treated
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary results from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease. These latest data show that, as of the February 14, 2022 cutoff date, the investigational treatment continued to be generally well tolerated, with no treatment-related adverse events above Grade 1 (mild). The five longest treated patients continued to exhibit elevated alpha-galactosidase A (α-Gal A) activity, sus
Aug 04, 2022 04:01 pm ET
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and second quarter 2022 financial results.
Jul 28, 2022 04:15 pm ET
Sangamo Therapeutics Announces Second Quarter 2022 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its second quarter 2022 financial results after the market closes on Thursday, August 4, 2022.
Jul 21, 2022 08:05 am ET
European Orphan Medicinal Product Designation Granted to Sangamo Therapeutics Investigational CAR-Treg Cell Therapy TX200 for Solid Organ Transplantation
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the European Commission (EC) has granted Orphan Medicinal Product Designation (OMPD) to TX200, a wholly-owned autologous Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) cell therapy product candidate for treatment in solid organ transplantation.
Jun 01, 2022 04:30 pm ET
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor conferences:
May 05, 2022 04:01 pm ET
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and first quarter 2022 financial results.
May 02, 2022 04:30 pm ET
Sangamo Therapeutics to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted eight Sangamo abstracts for presentation at the 25th ASGCT Annual Meeting being held May 16-19, 2022, in-person in Washington, D.C. and in a virtual format. Presentations will focus on the progression of Sangamo’s pre-clinical programs emerging from its genomic engineering platform.
Apr 28, 2022 04:15 pm ET
Sangamo Therapeutics Announces First Quarter 2022 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its first quarter 2022 financial results after the market closes on Thursday May 5, 2022. The press release will be followed by a conference call at 4:30 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review its financial results and provide business updates.
Apr 21, 2022 04:30 pm ET
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor conferences:
Apr 04, 2022 09:00 am ET
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Sangamo Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
NEW YORK, April 4, 2022 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Sangamo Therapeutics, Inc. (NASDAQ: SGMO).
Mar 29, 2022 08:05 am ET
Sangamo Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of Investigational CAR-Treg Cell Therapy TX200 in Kidney Transplantation
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced dosing of the first patient in the Phase 1/2 STEADFAST clinical study evaluating TX200, a wholly-owned autologous Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation from a living donor.
Feb 28, 2022 05:00 pm ET
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor conferences:
Feb 24, 2022 04:01 pm ET
Sangamo Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported fourth quarter and full year 2021 financial results and recent business highlights.
Feb 17, 2022 04:30 pm ET
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2021 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its fourth quarter and full year 2021 financial results after the market closes on Thursday, February 24, 2022. The press release will be followed by a conference call at 4:30 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide business updates.
Feb 07, 2022 06:00 pm ET
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients With Fabry Disease
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary results from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease. These latest data show that, as of the November 9, 2021 cutoff date, the investigational treatment continued to be well tolerated and that the four longest treated patients continued to exhibit elevated alpha-galactosidase A (α-Gal A) activity. These data are being presented at the 18th Annual WORLD
Jan 06, 2022 08:00 am ET
Sangamo Announces Transition of SAR445136 Sickle Cell Disease Program From Sanofi to Sangamo
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that Sanofi will be transitioning its rights and obligations related to SAR445136, a zinc finger nuclease gene-edited cell therapy candidate in development by Sangamo and Sanofi for the treatment of sickle cell disease (SCD), back to Sangamo over the first half of 2022. The Companies are collaborating on an orderly transition, while Sangamo explores options to advance the program, including seeking a new collaboration partner. This transition follows Sanofi’s termination for convenience of the Global Resear
Jan 04, 2022 05:00 pm ET
Sangamo Therapeutics Announces Participation at H.C. Wainwright BIOCONNECT Virtual Conference
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will provide a corporate presentation at the H.C. Wainwright BIOCONNECT Virtual Conference on Monday, January 10th at 7:00 a.m. Eastern Time.
Dec 12, 2021 04:30 pm ET
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy
Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A. The Alta study data, in patients with severe hemophilia A,
Dec 12, 2021 09:00 am ET
Sangamo Therapeutics Announces Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data Showing Tolerability and Sustained Effects in Sickle Cell Disease
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary proof-of-concept clinical data from the Phase 1/2 PRECIZN-1 study of SAR445136, a zinc finger nuclease gene-edited cell therapy candidate in development with Sanofi for the treatment of sickle cell disease (SCD). These data are being presented today at the 63rd American Society for Hematology Annual Meeting and Exposition taking place from December 11-14 virtually and in Atlanta, GA. The poster presentation, which includes follow-up data up to 91 weeks for the longest-treated p
Nov 22, 2021 07:00 am ET
Organogenesis Appoints Prathyusha Duraibabu to Board of Directors
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today...
Nov 09, 2021 08:30 am ET
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor conferences:
Nov 04, 2021 09:05 am ET
Sangamo Therapeutics Reports Recent Business and Clinical Highlights and Third Quarter 2021 Financial Results
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported third quarter financial results and provided business and clinical highlights.
Nov 04, 2021 08:00 am ET
Sangamo Therapeutics Announces Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients With Fabry Disease
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced preliminary results from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease. As of the September 17, 2021 cutoff date, results from the four patients treated in the first two dose cohorts (0.5e13 vg/kg and 1e13 vg/kg) showed that isaralgagene civaparvovec was generally well tolerated. All four patients exhibited above normal alpha-galactosidase A (α-Gal A) activity, which was maintained for up to
Oct 28, 2021 04:30 pm ET
Sangamo Therapeutics Announces Third Quarter 2021 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its third quarter 2021 financial results on Thursday, November 4, 2021. The press release will be followed by a conference call at 9:15 a.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide business and clinical updates.
Aug 31, 2021 08:30 am ET
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in fireside chats at the following investor conferences:
Aug 09, 2021 04:30 pm ET
Sangamo Therapeutics Announces Participation at 2021 Wedbush PacGrow Healthcare Conference
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will participate in a fireside chat at the 2021 Wedbush PacGrow Healthcare Conference on Wednesday, August 11th at 2:55pm Eastern Time.
Aug 05, 2021 04:01 pm ET
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and second quarter 2021 financial results.
Jul 29, 2021 04:30 pm ET
Sangamo Therapeutics Announces Second Quarter 2021 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its second quarter 2021 financial results after the market closes on Thursday, August 5, 2021. The press release will be followed by a conference call at 4:30 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide business updates.
May 24, 2021 04:15 pm ET
Sangamo Therapeutics Appoints Prathyusha Duraibabu, CPA, MBA, to Chief Financial Officer
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today the appointment of Prathyusha Duraibabu, CPA, MBA as Senior Vice President and Chief Financial Officer, effective June 1, 2021. Ms. Duraibabu will lead all financial activities and report to the Chief Executive Officer.
May 21, 2021 08:30 am ET
Sangamo Therapeutics Announces Participation at Jefferies Healthcare Conference
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 4th at 11am Eastern Time.
May 04, 2021 04:01 pm ET
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and first quarter 2021 financial results.
May 03, 2021 04:30 pm ET
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in fireside chats at the following investor conferences:
Apr 27, 2021 04:30 pm ET
Sangamo Therapeutics Announces Presentations at 2021 Annual Meeting of the American Society of Gene & Cell Therapy
Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today announced upcoming data presentations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) being held May 11-14, 2021, in a virtual format.
Apr 27, 2021 04:15 pm ET
Sangamo Therapeutics Announces First Quarter 2021 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its first quarter 2021 financial results after the market closes on Tuesday, May 4, 2021. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide business updates.
Mar 25, 2021 08:30 am ET
Sangamo Therapeutics Announces Participation at Guggenheim Healthcare Talks: 2021 Genomic Medicines & Rare Disease
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will participate in the virtual Guggenheim Healthcare Talks: 2021 Genomic Medicines & Rare Disease conference on April 1, 2021. Sangamo management is expected to participate in a panel discussion at 10 a.m. Eastern Time on April 1, 2021.
Mar 17, 2021 04:30 pm ET
Sangamo Announces EMA Releases Details Supporting Orphan Designation for BIVV003 for the Treatment of Sickle Cell Disease
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) released details supporting the Orphan Designation of BIVV003, an investigational ex vivo gene-edited cell therapy product candidate currently being evaluated for the treatment of sickle cell disease in the Phase 1/2 PRECIZN-1 study partnered with Sanofi. The Committee’s decision to grant Orphan Designation was based in part on early data from three patients that had 52 weeks, 13 weeks, and 29 days of follow-up, respec
Feb 24, 2021 04:01 pm ET
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported fourth quarter and full year 2020 financial results and recent business highlights.
Feb 18, 2021 04:15 pm ET
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor conferences:
Feb 17, 2021 04:15 pm ET
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2020 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its fourth quarter and full year 2020 financial results after the market closes on Wednesday, February 24, 2021. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide business updates.
Feb 01, 2021 04:05 pm ET
Sangamo Therapeutics Appoints Rob Schott, MD, MPH, FACC, as Head of Development; Elevates Jason Fontenot, PhD to Chief Scientific Officer
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today the appointment of Rob Schott, MD, MPH, FACC, as Senior Vice President and Head of Development. Dr. Schott will lead clinical strategy across all phases of development and regulatory approval and will report to Sandy Macrae, Sangamo’s Chief Executive Officer. Sangamo also announced today that, effective January 1, 2021, Jason Fontenot, PhD, has been promoted to Chief Scientific Officer. Dr. Fontenot has served as Sangamo’s Head of Cell Therapy since March 2019 and as the acting Interim Head of Research since
Jan 06, 2021 04:10 pm ET
Sangamo Therapeutics Announces Departure of Chief Financial Officer Sung Lee
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that Chief Financial Officer Sung Lee is leaving the Company to pursue a new opportunity overseas. Mr. Lee’s last day of employment will be February 1, 2021.
Jan 05, 2021 08:00 am ET
Sangamo Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13th at 5:20pm EST.
Dec 07, 2020 07:00 am ET
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels in 3x1013 VG/KG Cohort Through One Year Following Hemophilia A Gene Therapy
Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec (SB-525 or PF-07055480), an investigational gene therapy for patients with severe hemophilia A. These data are being presented today at the 62nd American Society for Hematology Annual meeting taking place virtually from December 5th - 8th. The oral presentation slides, which include follow-up data up to 85 weeks for the longest treated patient, are available
Nov 05, 2020 08:00 am ET
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the following investor conferences:
Nov 04, 2020 04:01 pm ET
Sangamo Therapeutics Reports Business Highlights and Third Quarter 2020 Financial Results
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported third quarter 2020 financial results and recent business highlights.
Oct 28, 2020 04:15 pm ET
Sangamo Therapeutics Announces Third Quarter 2020 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its third quarter 2020 financial results after the market closes on Wednesday, November 4, 2020. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide business updates.
Oct 07, 2020 06:45 am ET
Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment
Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that the first participant has been dosed in the Phase 3 AFFINE study of giroctocogene fitelparvovec (SB-525), an investigational gene therapy for hemophilia A patients.
Sep 28, 2020 08:30 am ET
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the following investor conferences:
Sep 11, 2020 08:30 am ET
Sangamo Therapeutics Appoints Kenneth Hillan to Its Board of Directors
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of Dr. Kenneth Hillan, an accomplished biotechnology executive, to the Company's Board of Directors.
Sep 02, 2020 04:15 pm ET
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the following investor conferences:
Aug 10, 2020 08:30 am ET
Sangamo Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that Sandy Macrae, CEO of Sangamo, will present at the 2020 Wedbush PacGrow Healthcare Conference on August 12, 2020 at 2:55 p.m. Eastern Time.
Aug 05, 2020 04:01 pm ET
Sangamo Therapeutics Reports Business Highlights and Second Quarter 2020 Financial Results
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported second quarter 2020 financial results and recent business highlights.
Jul 30, 2020 07:00 am ET
Sangamo Announces Global Collaboration With Novartis to Develop Genomic Medicines for Autism and Other Neurodevelopmental Disorders
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has executed a global licensing collaboration agreement with Novartis to develop and commercialize gene regulation therapies to address three neurodevelopmental targets, including autism spectrum disorder (ASD) and other neurodevelopmental disorders. The collaboration will leverage Sangamo’s propriety genome regulation technology, zinc finger protein transcription factors (ZFP-TFs), to aim to upregulate the expression of key genes involved in neurodevelopmental disorders.
Jul 29, 2020 04:15 pm ET
Sangamo Therapeutics Announces Second Quarter 2020 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its second quarter 2020 financial results after the market closes on Wednesday, August 5, 2020. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a business update.
Jun 24, 2020 08:00 am ET
Sangamo Announces R&D Organization Changes
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced changes to its research and development organization.
Jun 18, 2020 09:00 am ET
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (S
Pfizer Inc. (NYSE:PFE) and Sangamo Therapeutics, Inc. (Nasdaq:SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec (SB-525, or PF-07055480), an investigational gene therapy for patients with severe hemophilia A. All five patients with severe hemophilia A who received the 3e13 vg/kg dose showed sustained factor VIII (FVIII) activity levels, with a median of 64.2% via chromogenic assay (patient-level geometric means after week 9 post-infusion). No patients experienced bleeding events or required FVII
Jun 18, 2020 09:00 am ET
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (S
Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec (SB-525, or PF-07055480), an investigational gene therapy for patients with severe hemophilia A. All five patients with severe hemophilia A who received the 3e13 vg/kg dose showed sustained factor VIII (FVIII) activity levels, with a median of 64.2% via chromogenic assay (patient-level geometric means after week 9 post-infusion). No patients experienced bleeding events or required FVI
May 29, 2020 09:00 am ET
Sangamo Therapeutics Announces Participation at the Jefferies Virtual Healthcare Conference
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2 at 4:00 p.m. ET.
May 12, 2020 09:15 am ET
Sangamo Therapeutics Announces Participation at the Bank of America 2020 Health Care Conference
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the Bank of America 2020 Health Care Conference on Thursday, May 14 at 4:20 p.m. ET.
May 11, 2020 04:01 pm ET
Sangamo Therapeutics Reports Business Highlights and First Quarter 2020 Financial Results
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported first quarter 2020 financial results and recent business highlights.
May 07, 2020 05:15 pm ET
Sangamo Therapeutics Announces Virtual Format for 2020 Annual Meeting
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that it is changing its 2020 Annual Meeting of Stockholders to a virtual-only format due to public health and safety concerns related to the coronavirus (COVID-19) pandemic.
May 04, 2020 04:15 pm ET
Sangamo Therapeutics Announces First Quarter 2020 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its first quarter 2020 financial results after the market closes on Monday, May 11, 2020. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a business update.
Apr 28, 2020 04:30 pm ET
Sangamo Therapeutics Announces Presentations at 2020 Annual Meeting of the American Society of Gene & Cell Therapy
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the acceptance of several abstracts for presentation at the 23rd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) being held May 12th to May 15th, 2020, in a virtual format.
Apr 21, 2020 07:00 am ET
Mogrify and Sangamo announce collaboration and exclusive license agreement for Mogrify’s iPSC- and ESC-derived regulatory T cells
Mogrify Ltd (Mogrify®), a UK company aiming to transform the development of cell therapies by the systematic discovery of novel cell conversions, and Sangamo Therapeutics (Sangamo) (Nasdaq: SGMO), a genomic medicine company, today announced that they have executed a collaboration and exclusive license agreement for Sangamo to develop allogeneic cell therapies from Mogrify’s proprietary induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) and Sangamo’s zinc finger protein (ZFP) gene-engineered chimeric antigen receptor regulatory T cell (CAR-Treg) technology.
Apr 17, 2020 08:30 am ET
Sangamo Appoints D. Mark McClung as Executive Vice President and Chief Business Officer
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of D. Mark McClung as Executive Vice President and Chief Business Officer. Mr. McClung will oversee commercial strategic planning, alliance management and corporate and business development.
Apr 09, 2020 08:00 am ET
Sangamo Announces Closing of Biogen Collaboration Agreement
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the closing of its previously announced sale of stock to Biogen Inc. (Nasdaq: BIIB) and that the global licensing collaboration agreement with Biogen for the development and commercialization of gene regulation therapies for Alzheimer’s, Parkinson’s, neuromuscular and other neurological diseases is now effective. Under the terms of the collaboration, Sangamo has received $225 million from the purchase by Biogen of newly issued Sangamo stock and will receive an upfront license fee of $125 million from Biogen
Mar 02, 2020 08:30 am ET
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the following investor conferences:
Feb 28, 2020 07:00 am ET
Sangamo Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported fourth quarter and full year 2019 financial results and recent business highlights.
Feb 27, 2020 04:06 pm ET
Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases
Biogen Inc. (Nasdaq: BIIB) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that they have executed a global licensing collaboration agreement to develop and commercialize ST-501 for tauopathies including...
Feb 27, 2020 04:06 pm ET
Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases
Biogen Inc. (Nasdaq: BIIB) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that they have executed a global licensing collaboration agreement to develop and commercialize ST-501 for tauopathies including Alzheimer’s disease, ST-502 for synucleinopathies including Parkinson’s disease, a third undisclosed neuromuscular disease target, and up to nine additional undisclosed neurological disease targets. The companies will leverage Sangamo’s proprietary zinc finger protein (ZFP) technology delivered via adeno-associated virus (AAV) to modulate the expressi
Feb 25, 2020 04:30 pm ET
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2019 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its fourth quarter and full year 2019 financial results before market opens on Friday, February 28, 2020. The press release will be followed by a conference call at 8:00 a.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a business update.
Feb 12, 2020 08:00 am ET
Sangamo Therapeutics Appoints John Markels to Its Board of Directors
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of Dr. John Markels, an accomplished pharmaceutical executive with three decades of general management, manufacturing and technology experience at Merck, to the Sangamo Board of Directors.
Jan 09, 2020 08:30 am ET
Sangamo Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that Sandy Macrae, CEO of Sangamo, will present a corporate overview at the 38th Annual J.P. Morgan Healthcare Conference on Thursday, January 16th at 8:30 a.m. PT in San Francisco.
Dec 23, 2019 06:50 am ET
Sangamo Announces Early Completion of Transfer to Pfizer of SB-525 Hemophilia A Gene Therapy IND and an Earned $25 Million Milestone Payment
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today the completion of the transfer to Pfizer of the SB-525 Hemophilia A gene therapy Investigational New Drug application (IND). Pfizer is advancing SB-525 into a Phase 3 registrational clinical study in 2020 and has already commenced enrolling patients into a Phase 3 lead-in study. Sangamo has now earned a $25 million milestone payment, per the terms of a December 2019 amendment to the parties’ collaboration agreement for the global development and commercialization of gene therapies for Hemophilia A.
Dec 17, 2019 06:45 am ET
Sangamo Highlights Advancements in Genomic Medicine Pipeline and Expanded R&D and Manufacturing Capabilities at R&D Day
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, is hosting an R&D Day today beginning at 8am Eastern Time. During the event, Sangamo executives and scientists plan to provide updates across the Company’s clinical and preclinical pipeline, as well as an overview of manufacturing capabilities to support clinical and commercial supply. A live webcast link will be available on the
Dec 09, 2019 06:45 am ET
Sangamo Announces Preliminary Results From the First Three Patients in a Phase 1/2 Study Evaluating ST-400 Ex Vivo Gene-edited Cell Therapy in Beta Thalassemia
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced preliminary results from the first three patients treated in the Phase 1/2 THALES study evaluating investigational ST-400 ex vivo gene-edited cell therapy in transfusion-dependent beta thalassemia (TDT). The data are featured in a poster presentation on December 9, 2019 at the 61st Annual Meeting of the American Society of Hematology (ASH) in Orlando, FL. The ST-400 ASH poster will be available on Sangamo’s website in the Investors and Media section under
Dec 07, 2019 09:00 am ET
Sangamo and Pfizer Announce Updated Phase 1/2 Results Showing Sustained Increased Factor VIII Activity Through 44 Weeks Following SB-525 Gene Therapy Treatment
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, and Pfizer, Inc. (NYSE: PFE), today announced updated follow-up results from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy in patients with severe hemophilia A. The data showed that SB-525 was generally well tolerated and demonstrated sustained increased Factor VIII (FVIII) levels following treatment with SB-525 through to 44 weeks, the extent of follow-up for the longest treated patient in the 3e13 vg/kg dose cohort. Data from 11 patients treated with SB-525 will be featured in a poster presentati
Dec 06, 2019 08:30 am ET
Sangamo to Highlight Genomic Medicine Pipeline, Technology Platforms, and Manufacturing Capabilities in December 17 R&D Day
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the Company plans to host an R&D Day on December 17, 2019 at 8am Eastern Time in New York City. Sangamo executives and scientists will provide updates across the Company’s clinical and preclinical pipeline of genomic medicine product candidates, offer perspective on clinical data being presented at the upcoming American Society of Hematology Annual Meeting, and provide an overview of the Company’s manufacturing capabilities to support clinical and commercial supply.
Nov 26, 2019 08:30 am ET
Sangamo Therapeutics Appoints James R. Meyers to Its Board of Directors
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of James R. Meyers, an accomplished pharmaceutical executive with three decades of commercial experience, to the Company's Board of Directors.
Nov 19, 2019 07:00 am ET
Sangamo Announces UK Authorization of a Phase 1/2 Clinical Trial Evaluating the CAR-Treg Cell Therapy TX200 for Kidney Transplantation
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the United Kingdom’s (UK) Medicines Healthcare Products Regulatory Agency (MHRA) has granted authorization of the first-in-human clinical trial to evaluate a Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) therapy. TX200 is being studied for the prevention of immune-mediated rejection following HLA-A2 mismatched kidney transplantation for end-stage renal disease (ESRD). Sangamo expects to open the first clinical sites for the STEADFAST study in 2020.
Nov 18, 2019 04:05 pm ET
Sangamo Therapeutics Announces Participation at the Jefferies 2019 London Healthcare Conference
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the Jefferies 2019 London Healthcare Conference on Thursday, November 21 at 4:40 p.m. GMT in London, UK.
Nov 08, 2019 08:30 am ET
Sangamo Therapeutics Announces New Scientific Advisory Board
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that is has established a new Scientific Advisory Board (SAB). The SAB comprises an eclectic group of industry and academic experts who will advise Sangamo on its current and future clinical programs and research and development strategy.
Nov 06, 2019 04:01 pm ET
Sangamo Therapeutics Reports Third Quarter 2019 Financial Results
Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported third quarter 2019 financial results and recent business highlights.
Nov 06, 2019 09:00 am ET
Sangamo Announces Gene Therapy and Ex Vivo Gene-Edited Cell Therapy Data Presentations at the American Society of Hematology Annual Meeting
Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today announced that hemophilia A gene therapy clinical data and hemoglobinopathies ex vivo gene-edited cell therapy data will be featured in poster presentations at the 61st Annual Meeting of the American Society of Hematology (ASH). The ASH abstracts, which were submitted on August 3, 2019, were released online this morning. The conference will take place in Orlando, FL, from December 7-10, 2019.
Nov 01, 2019 08:01 am ET
Sangamo Therapeutics Appoints Sung Lee as Executive Vice President and Chief Financial Officer
Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, announced today the appointment of Sung Lee as Executive Vice President and Chief Financial Officer, effective October 31, 2019. Mr. Lee oversees finance, facilities and information technology functions for Sangamo and reports to the Chief Executive Officer.
Oct 30, 2019 04:15 pm ET
Sangamo Therapeutics Announces Third Quarter 2019 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its third quarter 2019 financial results after the market closes on Wednesday, November 6, 2019. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a business update.
Sep 30, 2019 04:15 pm ET
Sangamo Therapeutics Appoints Bettina M. Cockroft, MD, MBA, as Senior Vice President and Chief Medical Officer
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today the appointment of Bettina M. Cockroft, MD, MBA, as Senior Vice President and Chief Medical Officer. Dr. Cockroft will oversee all clinical development activities and operations and will report to the Executive Vice President of Research and Development.
Sep 30, 2019 08:30 am ET
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that members of the management team will present at the following investor and industry conferences in October:
Aug 30, 2019 08:30 am ET
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the following investor conferences in September:
Aug 07, 2019 04:01 pm ET
Sangamo Therapeutics Reports Second Quarter 2019 Financial Results
Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported second quarter 2019 financial results and recent business highlights.
Aug 06, 2019 04:05 pm ET
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that CEO Sandy Macrae will present at the 2019 Wedbush PacGrow Healthcare Conference in New York City. The presentation is scheduled for Wednesday, August 14 at 1:20 p.m. Eastern Time.
Jul 31, 2019 04:15 pm ET
Sangamo Therapeutics Appoints Gary H. Loeb as Executive Vice President and General Counsel
Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, announced today the appointment of Gary H. Loeb as Executive Vice President and General Counsel, effective immediately. Mr. Loeb will oversee all legal matters for Sangamo and will report to the Chief Executive Officer.
Jul 31, 2019 04:05 pm ET
Sangamo Therapeutics Announces Second Quarter 2019 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company will release its second quarter 2019 financial results after the market closes on Wednesday, August 7, 2019. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a business update.
Jul 29, 2019 11:00 am ET
Sangamo Announces Nature Biotechnology Publication of New Strategies for Optimizing the Specificity of Gene Editing Nucleases
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today the publication in Nature Biotechnology of a manuscript by Jeffrey Miller, Ph.D., and colleagues at Sangamo, describing two new strategies for optimizing the specificity of genome editing using zinc finger nucleases (ZFNs). The ability to engineer highly specific gene editing nucleases with little or no detectable activity at unintended genomic sequences is a key safety factor for therapeutic applications. The strategies entail engineering the two key functional regions within the ZFN structure, namel
Jul 08, 2019 09:31 am ET
Thinking about buying stock in Apple, Aurora Cannabis, Oasmia Pharmaceutical, Sangamo Therapeutics, or Symantec?
NEW YORK, July 8, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, ACB, OASM, SGMO, and SYMC.
Jul 05, 2019 11:15 pm ET
Sangamo and Pfizer Announce Updated Phase 1/2 Results for SB-525 Investigational Hemophilia A Gene Therapy Showing Sustained Increased Factor VIII Levels
Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, and Pfizer, Inc. (NYSE: PFE) today announced updated results from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy for severe hemophilia A. The data showed that SB-525 was generally well-tolerated and demonstrated a dose-dependent increase in Factor VIII (FVIII) activity levels. The first two patients treated at the 3e13 vg/kg dose rapidly achieved normal levels of FVIII activity as measured using a chromogenic assay, with no reported bleeding events, and the response continues to be durable for as lo
Jul 01, 2019 11:00 am ET
 Sangamo Therapeutics Announces Nature Medicine Publication Detailing the Activity of Disease Allele-Selective Zinc Finger Proteins in Preclinical Models of Huntington’s Disease
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the publication of a manuscript describing the activity of allele-selective zinc finger protein transcription-factors (ZFP-TFs) in preclinical models of Huntington’s disease (HD). The data were published online on July 1 and will appear in the July 2019 issue of Nature Medicine.
May 15, 2019 04:30 pm ET
Sangamo Therapeutics Announces Presentations At Upcoming Scientific, Medical And Investor Conferences
BRISBANE, Calif., May 15, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today announced participation in the following scientific, medical, and investor conferences:
May 10, 2019 08:30 am ET
Sangamo Therapeutics Announces Participation In The Bank Of America Merrill Lynch 2019 Health Care Conference
BRISBANE, Calif., May 10, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO) announced today that Sangamo will participate in the Bank of America Merrill Lynch 2019 Health Care Conference being held next week in Las Vegas. A "fireside chat" discussion with Sangamo CEO Sandy Macrae is scheduled for Tuesday, May 14th at 5 p.m. PT.
May 08, 2019 04:01 pm ET
Sangamo Therapeutics Reports First Quarter 2019 Financial Results
BRISBANE, Calif., May 8, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported first quarter 2019 financial results and recent business highlights.
May 01, 2019 04:01 pm ET
Sangamo Therapeutics Announces First Quarter 2019 Conference Call And Webcast
BRISBANE, Calif., May 1, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company will release its first quarter 2019 financial results after the market closes on Wednesday, May 8, 2019. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a business update.
Apr 15, 2019 04:01 pm ET
Sangamo Therapeutics Announces Presentations At 2019 Annual Meeting Of The American Society Of Gene & Cell Therapy
BRISBANE, Calif., April 15, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today announced that Sangamo scientists and collaborators will present data from the Company's clinical and preclinical pipeline at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) being held April 29th to May 2nd, 2019 in Washington, D.C. 
Apr 08, 2019 04:01 pm ET
Sangamo Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
RICHMOND, Calif., April 8, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced the completion of its previously announced underwritten public offering of 12,650,000 shares of its common stock at a price to the public of $11.50 per share, including 1,650,000 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares. All of the shares were sold by Sangamo. Including the option exercise, the aggregate gross proceeds to Sangamo from the offering, before deducting the underwriting discounts and commissions and offering expens
Apr 04, 2019 08:00 am ET
Sangamo Therapeutics Announces Pricing of Public Offering of Common Stock
RICHMOND, Calif., April 4, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a price to the public of $11.50 per share. All of the shares are being sold by Sangamo. The gross proceeds to Sangamo from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be approximately $126.5 million. The offering is expected to close on or about April 8, 2019, subject to customary closing conditions. In addition, Sangamo has grant
Apr 03, 2019 04:01 pm ET
Sangamo Therapeutics Announces Proposed Public Offering of Common Stock
RICHMOND, Calif., April 3, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares are being offered by Sangamo. In addition, Sangamo expects to grant the underwriters of the offering a 30-day option to purchase additional shares of its common stock at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering will be completed, or
Apr 02, 2019 09:31 am ET
Thinking about buying stock in Cronos Group Inc., Facebook Inc., InspireMD Inc., Pulmatrix Inc., or Sangamo Therapeutics?
NEW YORK, April 2, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CRON, FB, NSPR, PULM, and SGMO.
Apr 02, 2019 07:00 am ET
Sangamo and Pfizer Announce Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy
BRISBANE, Calif. and NEW YORK, April 2, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, and Pfizer, Inc. (NYSE: PFE) today announced interim data from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy for severe hemophilia A. Data indicate that SB-525 was generally well-tolerated and demonstrated a dose-dependent increase in Factor VIII (FVIII) levels across the four dosage cohorts. Eight patients total were dosed. Based on these results, the Safety Monitoring Committee (SMC) recommended cohort expansion at the 3e13 vg/kg dose
Apr 02, 2019 07:00 am ET
Sangamo and Pfizer Announce Phase 1/2 Interim Data for Investigational Hemophilia A Gene Therapy
Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, and Pfizer, Inc. (NYSE: PFE) today announced interim data from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy for severe hemophilia A. Data indicate that SB-525 was generally well-tolerated and demonstrated a dose-dependent increase in Factor VIII (FVIII) levels across the four dosage cohorts. Eight patients total were dosed. Based on these results, the Safety Monitoring Committee (SMC) recommended cohort expansion at the 3e13 vg/kg dose. Further deta
Apr 02, 2019 07:00 am ET
Sangamo Announces Agreement Securing Access To Large-Scale, Commercial-Grade Manufacturing Capacity At Brammer Bio
BRISBANE, Calif., April 2, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced it has signed an option agreement with Brammer Bio, a gene therapy contract development and manufacturing organization, to secure access to large-scale AAV manufacturing. Additionally, at Sangamo's new facilities in Brisbane, California, construction is underway of a Phase 1/2 cGMP manufacturing facility, which is expected to be operational in 2020.
Apr 02, 2019 07:00 am ET
Sangamo Provides Clinical Development Update Including Early Phase 1/2 Beta Thalassemia Gene-edited Cell Therapy Data
BRISBANE, Calif., April 2, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today announced recent progress across its clinical portfolio, including early data for ST-400, an ex vivo gene-edited beta thalassemia cell therapy developed in partnership with Sanofi, and next steps for its in vivo genome editing programs. Additionally, in separate announcements, Sangamo today also provided an update on its AAV manufacturing capacity and capabilities, and in a joint press release with partner Pfizer, reported interim data from the SB-525 hemophilia A gene
Apr 01, 2019 04:43 pm ET
Sangamo Therapeutics To Host April 2, 2019 Conference Call To Provide Clinical Update
BRISBANE, Calif., April 1, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will host a conference call on Tuesday, April 2nd at 8:00 a.m. Eastern Time to provide a clinical development update.
Mar 29, 2019 07:00 am ET
Sangamo Therapeutics Presents New Preclinical Data Demonstrating Significant Reduction In Tau Expression With Gene Regulation Technology
BRISBANE, Calif., March 29, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, presented new preclinical data demonstrating significant (>80%) reduction of tau expression in the nonhuman primate brain following administration of zinc finger protein transcription factors (ZFP-TFs). Tau pathology is strongly linked to the progression of several neurodegenerative diseases, called tauopathies, including Alzheimer's disease. The data, reported in a podium presentation at the 14th International Conference on Alzheimer's & Parkinson's Diseases (ADPD)
Mar 25, 2019 07:30 am ET
Report: Exploring Fundamental Drivers Behind M.D.C., salesforce.com, inc, Citrix, Match Group, Sangamo Therapeutics, and Popular — New Horizons, Emerging Trends, and Upcoming Developments
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of M.D.C. Holdings, Inc. (NYSE:MDC), salesforce.com, inc. (NYSE:CRM),...
Mar 12, 2019 07:00 am ET
Sangamo Therapeutics Appoints Jason Fontenot, Ph.D., As Senior Vice President, Cell Therapy
BRISBANE, Calif., March 12, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, announced today the appointment of Jason Fontenot, Ph.D., as Senior Vice President, Cell Therapy. Dr. Fontenot will oversee Sangamo's growing engineered cell therapy portfolio, including a proprietary immunology pipeline based on chimeric antigen receptor regulatory T cells (CAR-Tregs), a partnership with Sanofi focused on ex vivo genome-editing programs in hemoglobinopathies, and a partnership with Kite, a Gilead Company, to develop allogeneic CAR-T cell therapies in oncol
Mar 08, 2019 04:00 am ET
Sangamo Therapeutics Announces Publication Of Data Demonstrating New Zinc Finger Nuclease Architectures Enabling High-Precision Genome Editing
BRISBANE, Calif., March 8, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, announced today the publication in Nature Communications of improvements to its zinc finger nuclease (ZFN) platform technology, which yield a 64-fold increase in the diversity of ZFNs available for targeting any DNA segment. As demonstrated in the manuscript, this improved targeting capability enables highly precise editing of chosen genomic loci. ZFN technology is an engineerable gene editing platform that is currently being evaluated in clinical trials for Mucopolysacchar
Mar 06, 2019 03:01 pm ET
Sangamo Therapeutics Announces Participation At Upcoming Investor Conferences
BRISBANE, Calif., March 6, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will participate in the following healthcare investor conferences in March:
Feb 28, 2019 03:01 pm ET
Sangamo Therapeutics Reports Fourth Quarter And Full Year 2018 Financial Results
BRISBANE, Calif., Feb. 28, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported fourth quarter and full year 2018 financial results and recent business highlights.
Feb 21, 2019 03:01 pm ET
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2018 Conference Call and Webcast
BRISBANE, Calif., Feb. 21, 2019  /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company will release its fourth quarter and full year 2018 financial results after the market closes on Thursday, February 28, 2019. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a business update.
Feb 21, 2019 07:55 am ET
Investor Expectations to Drive Momentum within Sangamo Therapeutics, AVEO Pharmaceuticals, Everbridge, Huntington Ingalls Industries, Woodward, and SAP SE — Discovering Underlying Factors of Influence
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Sangamo Therapeutics, Inc. (NASDAQ:SGMO), AVEO Pharmaceuticals, Inc....
Feb 20, 2019 06:30 am ET
Sangamo Announces FDA Acceptance of IND Application for ST-920 Gene Therapy Candidate for Fabry Disease
BRISBANE, Calif., Feb. 20, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for ST-920, a gene therapy candidate being evaluated for the treatment of adults with Fabry disease. Current standard of care for this rare, progressive condition involves regular lifelong infusions of enzyme replacement therapy (ERT).
Feb 07, 2019 10:00 am ET
Sangamo Announces Interim Results Of Phase 1/2 CHAMPIONS Study Showing Preliminary Evidence Of In Vivo Genome Editing In Patients With MPS II Treated With SB-913
BRISBANE, Calif., Feb. 7, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO) today reported preliminary molecular and enzymatic evidence of editing of the human genome in vivo (inside the body). These findings are part of the interim results from the Phase 1/2 CHAMPIONS Study evaluating SB-913, a zinc finger nuclease (ZFN) in vivo genome editing product candidate for the treatment of patients with Mucopolysaccharidosis Type II (MPS II). These interim results were presented today at the WORLDSymposium 2019 being held in Orlando, Florida. Also reported today were interim results fr
Feb 07, 2019 10:00 am ET
Sangamo Announces Interim Results Of Phase 1/2 EMPOWERS Study Evaluating SB-318 Zinc Finger Nuclease (ZFN) In Vivo Genome Editing Demonstrating Increased Leukocyte IDUA Activity In Patients With MPS I
BRISBANE, Calif., Feb. 7, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO) today presented interim data from the Phase 1/2 EMPOWERS Study evaluating the SB-318 zinc finger nuclease (ZFN) in vivo (inside the body) genome editing product candidate in patients with Mucopolysaccharidosis Type I (MPS I). These data, along with interim results of the CHAMPIONS Study evaluating SB-913 for MPS II, were presented today at the WORLDSymposium 2019 being held in Orlando, Florida. Sangamo believes data from these two studies provide complementary evidence supportive of a favorable safety pr
Feb 01, 2019 07:30 am ET
Sangamo Therapeutics To Host Conference Call To Review Interim Results From Phase 1/2 CHAMPIONS And EMPOWERS Studies For MPS II And MPS I
BRISBANE, Calif., Feb. 1, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will host a conference call on February 7th at 12:30 p.m. Eastern Time to discuss interim clinical results from the Phase 1/2 CHAMPIONS and EMPOWERS studies evaluating SB-913 and SB-318 zinc finger nuclease (ZFN)  in vivo genome editing product candidates for mucopolysaccharidosis type II (MPS II) and MPS I, respectively. The call will follow presentations earlier that morning at the 2019 WORLDSymposium in Orlando, Florida.
Jan 29, 2019 07:45 am ET
Investor Expectations to Drive Momentum within Dollar General, Zayo Group, Cabot Oil & Gas, Sangamo Therapeutics, BioTelemetry, and Dean Foods — Discovering Underlying Factors of Influence
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Dollar General Corporation (NYSE:DG), Zayo Group Holdings, Inc....
Jan 22, 2019 03:05 pm ET
Sangamo Therapeutics Appoints Adrian Woolfson, BM., B.Ch., Ph.D., As Executive Vice President Of Research And Development
RICHMOND, Calif., Jan. 22, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of Adrian Woolfson, BM BCh, PhD, as Executive Vice President of Research and Development, effective January 22, 2019. Dr. Woolfson will oversee discovery, research and development activities for the Company and will report to Sandy Macrae.
Jan 04, 2019 07:00 am ET
Sangamo Announces Upcoming Clinical Data Presentations At WORLDSymposium 2019
RICHMOND, Calif., Jan. 4, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that interim clinical data from the Company's inherited metabolic diseases development programs will be presented at WORLDSymposium, an annual conference dedicated to lysosomal diseases being held February 4-8th, 2019 at the Hyatt Regency Orlando in Orlando, Florida.
Jan 04, 2019 07:00 am ET
Sangamo Therapeutics To Present at the 37th Annual J.P. Morgan Healthcare Conference
RICHMOND, Calif., Jan. 4, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO) announced today that Sandy Macrae, CEO of Sangamo, will present a corporate overview at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9th at 11:30 a.m. PT in San Francisco. Dr. Macrae's presentation will be followed by a separate Q&A session starting at 12:00 p.m. PT.
Dec 17, 2018 07:00 am ET
Sangamo Announces Treatment Of First Patient In Phase 1/2 Clinical Trial Of In Vivo Genome Editing Therapy For Hemophilia B
RICHMOND, Calif., Dec. 17, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomics medicines company, today announced treatment of the first patient in the Phase 1/2 clinical trial evaluating SB-FIX, an investigational in vivo genome editing therapy for patients with hemophilia B.
Dec 03, 2018 06:00 am ET
Sangamo Announces Completion Of TxCell Acquisition
RICHMOND, Calif. and VALBONNE, France, Dec. 3, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced the completion of the acquisition of TxCell, SA. TxCell is now a subsidiary of Sangamo and has been delisted from the French stock market.
Nov 28, 2018 08:45 am ET
Report: Developing Opportunities within Costco Wholesale, Pepsico, Northern Oil and Gas, Codexis, Sangamo Therapeutics, and BRF S.A. — Future Expectations, Projections Moving into 2018
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Costco Wholesale Corporation (NASDAQ:COST), Pepsico, Inc. (NASDAQ:PEP),...
Nov 08, 2018 03:01 pm ET
Sangamo Therapeutics Reports Third Quarter 2018 Financial Results
RICHMOND, Calif., Nov. 8, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO) today reported third quarter 2018 financial results and recent business highlights.
Nov 06, 2018 03:01 pm ET
Sangamo Therapeutics Announces Participation At Upcoming Investor Conferences
RICHMOND, Calif., Nov. 6, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that management will participate in the following healthcare investor conferences in November.
Nov 01, 2018 08:30 am ET
Sangamo Therapeutics Announces Third Quarter 2018 Conference Call and Webcast
RICHMOND, Calif., Nov. 1, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that the Company will release its third quarter 2018 financial results after the market closes on Thursday, November 8, 2018. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a business update.
Oct 17, 2018 08:45 am ET
Analysis: Positioning to Benefit within New York, KB Home, Sangamo Therapeutics, INTL FCStone, Maiden, and MobileIron — Research Highlights Growth, Revenue, and Consolidated Results
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of New York Company, Inc. (NYSE:NWY), KB Home (NYSE:KBH), Sangamo...
Oct 01, 2018 08:00 am ET
Sangamo and TxCell announce the completion of the acquisition by Sangamo of majority of TxCell ordinary shares
RICHMOND, Calif. and VALBONNE, France, Oct. 1, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) and TxCell S.A. (ENXTPA: TXCL) today jointly announced the completion by Sangamo of the acquisition of ordinary shares of TxCell, at a price of €2.58 per share in cash, representing approximately 53% of the share capital and voting rights of TxCell, as per the terms of the Share Purchase Agreement entered into on July 20, 2018 (the "SPA") and announced previously by TxCell and Sangamo in a joint press release dated July 23, 2018. TxCell will now operate as a subsidiary of Sangamo. 
Sep 24, 2018 04:15 pm ET
Sangamo Therapeutics Announces Participation At Upcoming Investor and Industry Conferences
RICHMOND, Calif., Sept. 24, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that management will participate in the following healthcare investor and industry conferences in September and October.
Sep 05, 2018 08:14 am ET
Sangamo Announces 16 Week Clinical Results Including Reductions In Glycosaminoglycans In Phase 1/2 Trial Evaluating SB-913, A Zinc Finger Nuclease Genome Editing Treatment For MPS II (Hunter Syndrome)
RICHMOND, Calif., Sept. 5, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO) today reported 16 week reductions in urinary glycosaminoglycans (GAGs), a key biomarker of Mucopolysaccharidosis Type II (MPS II) disease pathophysiology, in Cohort 2 of the Phase 1/2 CHAMPIONS Study evaluating SB-913.  SB-913 is a zinc finger nuclease (ZFN) in vivo genome editing product candidate being evaluated for the treatment of MPS II, also known as Hunter syndrome. In Cohort 2 at 16 weeks post-dosing, mean reductions were observed in total urinary GAGs, dermatan sulfate, and heparan sulfate of 5
Aug 30, 2018 08:00 am ET
Sangamo Therapeutics Announces Conference Call To Review SB-913 CHAMPIONS Study Data And Participation At Upcoming Investor Conferences
RICHMOND, Calif., Aug. 30, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that management will host a conference call on September 5th at 9:00 a.m. ET to discuss clinical data from the CHAMPIONS Study, the Company's Phase 1/2 trial evaluating SB-913 in vivo genome editing therapeutic candidate for MPS II. The call will follow the presentation of the data earlier that day at the 2018 Symposium of the Society for the Study of Inborn Errors of Metabolism in Athens, Greece.
Aug 23, 2018 08:10 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Aurora Cannabis, Canopy Growth, MobileIron, Sangamo Therapeutics, BioDelivery Sciences International, and First Solar — New Research
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Aurora Cannabis Inc. (OTC:ACBFF), Canopy Growth Corporation (NYSE:CGC),...
Aug 10, 2018 08:00 am ET
Sangamo Therapeutics Announces Presentation At The 2018 Wedbush PacGrow Healthcare Conference
RICHMOND, Calif., Aug. 10, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO) announced today that management will present a corporate overview at the 2018 Wedbush PacGrow Healthcare Conference in New York City. The presentation is scheduled for Tuesday, August 14th at 4:15 p.m. ET.
Aug 08, 2018 04:01 pm ET
Sangamo Announces Positive Preliminary Data from the Phase 1/2 Alta Study Evaluating SB-525 Gene Therapy for Hemophilia A
RICHMOND, Calif., Aug. 8, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced positive preliminary data from the Phase 1/2 clinical trial evaluating SB-525, a cDNA gene therapy candidate for Hemophilia A (the "Alta study"). SB-525 is being developed as part of a global collaboration between Sangamo and Pfizer Inc. for the development and commercialization of potential gene therapy programs for Hemophilia A.
Aug 08, 2018 04:01 pm ET
Sangamo Therapeutics Reports Second Quarter 2018 Financial Results
RICHMOND, Calif., Aug. 8, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO) today reported second quarter 2018 financial results and recent accomplishments.
Aug 02, 2018 08:00 am ET
Sangamo Therapeutics Announces Second Quarter 2018 Conference Call and Webcast
RICHMOND, Calif., Aug. 2, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that the Company will release its second quarter 2018 financial results after the market closes on Wednesday, August 8, 2018. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a business update.
Jul 31, 2018 04:01 pm ET
Sangamo Announces Preliminary Data From Champions Study Evaluating SB-913, An Investigational Genome Editing Treatment For MPS II, To Be Presented September 5th At SSIEM 2018 Symposium
RICHMOND, Calif., July 31, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that preliminary safety and efficacy data from the CHAMPIONS Study, a Phase 1/2 clinical trial evaluating SB-913 for the treatment of mucopolysaccharidosis Type II (MPS II, also known as Hunter syndrome), will be presented at the 2018 Annual Symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM) being held in Athens, Greece from September 4-7th.
Jul 27, 2018 08:30 am ET
Sangamo To Host Educational Webcast With Hunter Syndrome (MPS II) Expert, Joseph Muenzer, M.D., Ph.D.
RICHMOND, Calif., July 27, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that the Company will host a webcast to review mucopolysaccharidosis Type II (MPS II, or Hunter syndrome) disease biology, standard of care treatment options, and scientific rationale for the development of SB-913, Sangamo's investigational in vivo genome editing treatment for MPS II. The webcast is scheduled for 2 p.m. Eastern Time on Wednesday, August 1, 2018.
Jul 23, 2018 07:00 am ET
Sangamo Announces Treatment Of First Patient In Phase 1/2 Clinical Trial Evaluating SB-318 Investigational In Vivo Genome Editing Therapy For MPS I
RICHMOND, Calif., July 23, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced treatment of the first patient in the Phase 1/2 clinical trial evaluating SB-318, an investigational in vivo genome editing therapy for patients with mucopolysaccharidosis type I (MPS I, Hurler syndrome) (the "EMPOWERS Study").
Jul 23, 2018 02:30 am ET
Sangamo Therapeutics to Acquire TxCell
RICHMOND, Calif. and VALBONNE, France, July 23, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) and TxCell S.A. (ENXTPA: TXCL) announced today that they have entered into a definitive agreement on July 20, 2018 pursuant to which Sangamo will, following the completion of the contemplated acquisition of a majority stake of TxCell, file a simplified cash tender offer for the purchase of all then outstanding ordinary shares of TxCell, at a price of €2.58 per share in cash, or approximately €72 million, on a debt-free and cash-free basis. Subject to satisfaction of closing conditio
Jul 13, 2018 04:15 pm ET
Sangamo Therapeutics Announces Technology Leadership Changes
RICHMOND, Calif., July 13, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced that Michael Holmes, Ph.D., Senior Vice President and Chief Technology Officer, will resign from the Company effective July 20th to pursue an opportunity with a startup biotech company. Edward Rebar, Ph.D., has been named Senior Vice President and Chief Technology Officer, effective immediately.
Jun 28, 2018 04:05 pm ET
Sangamo Therapeutics Appoints Karen Smith to its Board of Directors
RICHMOND, Calif., June 28, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced the appointment of Dr. Karen Smith, an accomplished drug development executive, to the Company's Board of Directors.
Jun 13, 2018 08:30 am ET
New Research Coverage Highlights Accenture, Chico's FAS, The Allstate, Sangamo Therapeutics, ABB, and First Internet — Consolidated Revenues, Company Growth, and Expectations for 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Accenture PLC (NYSE:ACN), Chico's FAS, Inc. (NYSE:CHS), The Allstate...
Jun 04, 2018 08:00 am ET
Sangamo Announces U.K. Authorization Of Clinical Trials Evaluating Zinc Finger Nuclease In Vivo Genome Editing Treatments SB-318 For MPS I And SB-913 For MPS II
RICHMOND, Calif., June 4, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom has granted the Clinical Trial Authorisation (CTA) for enrollment of subjects into ongoing Phase 1/2 clinical trials evaluating SB-318 and SB-913, zinc finger nuclease (ZFN) in vivo genome editing treatments for Mucopolysaccharidosis Type I (MPS I) and MPS II, respectively.
May 16, 2018 07:30 am ET
Bioverativ and Sangamo Announce FDA Acceptance of IND Application for Gene-Edited Cell Therapy BIVV003 to Treat Sickle Cell Disease
Bioverativ Inc., a Sanofi company dedicated to transforming the lives of people with rare blood disorders, and Sangamo Therapeutics, Inc. (NASDAQ:SGMO) announced today that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for BIVV003, a gene-edited cell therapy candidate for the treatment of people with sickle cell disease. Bioverativ and Sangamo are developing BIVV003 as part of an exclusive worldwide collaboration to develop and commercialize gene-edited cell therapies for sickle cell dise
May 08, 2018 07:00 am ET
Sangamo Therapeutics Reports First Quarter 2018 Financial Results
RICHMOND, Calif., May 8, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO) today reported first quarter 2018 financial results and recent accomplishments.
May 03, 2018 04:30 pm ET
Sangamo Therapeutics Announces Senior Leadership Changes
RICHMOND, Calif., May 3, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced that Senior Vice President and Chief Business Officer, Curt A. Herberts, III will resign from the Company effective June 1, 2018 to pursue a leadership opportunity with a private biotech company. 
May 01, 2018 04:01 pm ET
Sangamo Therapeutics Announces First Quarter 2018 Conference Call and Webcast
RICHMOND, Calif., May 1, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that the company will release its first quarter 2018 financial results before the market opens on Tuesday, May 8, 2018. The press release will be followed by a conference call at 8:00 a.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review its financial results and provide a business update.
May 01, 2018 08:00 am ET
Sangamo Therapeutics Announces Presentations At 2018 Annual Meeting Of The American Society Of Gene & Cell Therapy
RICHMOND, Calif., May 1, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO) today announced that data from the Company's technology and preclinical research programs will be presented at the 21st Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) being held May 16-19, 2018 in Chicago. Sangamo scientists or collaborators will present abstracts highlighting recent enhancements to Sangamo's zinc finger-based genome editing and gene regulation platforms; data from the company's preclinical development programs in Fabry disease, CNS disorders, and T cell immunot
Apr 30, 2018 04:01 pm ET
Sangamo Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
RICHMOND, Calif., April 30, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced the completion of its previously announced underwritten public offering of 14,156,500 shares of its common stock at a price to the public of $16.25 per share, including 1,846,500 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares. All of the shares were sold by Sangamo. Including the option exercise, the aggregate gross proceeds to Sangamo from the offering, before deducting the underwriting discounts and commissions and offering e
Apr 27, 2018 08:30 am ET
Sangamo Announces $8 Million CIRM Grant For ST-400 -- A Gene-Edited Cell Therapy Candidate -- To Treat Transfusion-Dependent Beta-Thalassemia
RICHMOND, Calif., April 27, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO) announced today that the California Institute for Regenerative Medicine (CIRM) has awarded an $8 million grant for Sangamo to evaluate ST-400, a gene-edited cell therapy candidate for people with transfusion-dependent beta-thalassemia.
Apr 25, 2018 09:10 pm ET
Sangamo Therapeutics Announces Pricing of Public Offering of Common Stock
RICHMOND, Calif., April 25, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced the pricing of an underwritten public offering of 12,310,000 shares of its common stock at a price to the public of $16.25 per share. All of the shares are being sold by Sangamo. The gross proceeds to Sangamo from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be approximately $200.0 million. The offering is expected to close on or about April 30, 2018, subject to customary closing conditions. In addition, Sangamo has gra
Apr 24, 2018 04:02 pm ET
Sangamo Therapeutics Announces Proposed Public Offering of Common Stock
RICHMOND, Calif., April 24, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced that it has commenced an underwritten public offering of $200.0 million of shares of its common stock. All of the shares are being offered by Sangamo. In addition, Sangamo expects to grant the underwriters of the offering a 30-day option to purchase up to an additional $30.0 million of shares of its common stock solely to cover overallotments at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there c
Apr 04, 2018 07:30 am ET
Sangamo Announces Publication In Molecular Therapy Of Preclinical Study Data From MPS II In Vivo Genome Editing Program
RICHMOND, Calif., April 4, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO) announced today the publication of preclinical murine study data from the company's in vivo genome editing program for Mucopolysaccharidosis Type II (MPS II) in the April 2018 issue of Molecular Therapy.  In the study, in a mouse model of MPS II, zinc finger nuclease (ZFN)-mediated genome editing of cells in the liver resulted in expression of therapeutic levels of iduronate 2-sulfatase (IDS), an enzyme MPS II patients lack, and in the prevention of metabolic and neurological disease symptoms. The work
Mar 21, 2018 03:06 pm ET
Glancy Prongay & Murray LLP Announces Investigation on Behalf of Sangamo Therapeutics, Inc. Investors (SGMO)
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Sangamo Therapeutics, Inc. (NASDAQ: SGMO) investors concerning the Company and its directors’ and officers’ possible violations of state laws.
Mar 05, 2018 03:01 pm ET
Sangamo Therapeutics Announces Presentations At Upcoming Investor Conferences
RICHMOND, Calif., March 5, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that Dr. Sandy Macrae, CEO of Sangamo, is scheduled to participate in the following healthcare investor conferences in March.
Mar 02, 2018 03:10 pm ET
Sangamo Therapeutics, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
RICHMOND, Calif., March 2, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that the Compensation Committee of the Company's Board of Directors has approved the grant effective on February 28, 2018 of inducement stock options to purchase 200,000 shares of common stock to Heather D. Turner, J.D., Senior Vice President and General Counsel.
Feb 28, 2018 06:30 am ET
Sangamo Announces U.K. Authorization Of Clinical Trial Evaluating Zinc Finger Nuclease In Vivo Genome Editing Treatment For Hemophilia B
RICHMOND, Calif., Feb. 28, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom has granted the Clinical Trial Authorisation (CTA) for enrollment of subjects into the ongoing Phase 1/2 clinical trial evaluating SB-FIX, a zinc finger nuclease (ZFN)-mediated in vivo genome editing treatment for hemophilia B. The CTA allows for initiation of Europe's first in vivo genome editing study.
Feb 23, 2018 07:30 am ET
Recent Analysis Shows Coherent, Xenia Hotels & Resorts, Career Education, Splunk, Sangamo Therapeutics, and Williams-Sonoma Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Feb. 23, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Coherent, Inc. (NASDAQ:COHR), Xenia Hotels &...
Feb 22, 2018 07:00 am ET
Kite, a Gilead Company, and Sangamo Therapeutics Announce Collaboration to Develop Next-Generation Engineered Cell Therapies for the Treatment of Cancer
Kite, a Gilead Company (Nasdaq:GILD) and Sangamo Therapeutics, Inc. (Nasdaq:SGMO) today announced the companies have entered into a worldwide collaboration using Sangamo’s zinc finger nuclease (ZFN) technology platform for the development of next-generation ex vivo cell therapies in oncology.
Feb 22, 2018 06:00 am ET
Kite, a Gilead Company, And Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For The Treatment Of Cancer
SANTA MONICA, Calif. and RICHMOND, Calif., Feb. 22, 2018 /PRNewswire/ -- Kite, a Gilead Company (Nasdaq: GILD) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced the companies have entered into a worldwide collaboration using Sangamo's zinc finger nuclease (ZFN) technology platform for the development of next-generation ex vivo cell therapies in oncology. 
Feb 22, 2018 06:00 am ET
Sangamo Therapeutics Reports Fourth Quarter And Full Year 2017 Financial Results
RICHMOND, Calif., Feb. 22, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO) today reported its fourth quarter and full year 2017 financial results and recent accomplishments.
Feb 20, 2018 06:00 am ET
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2017 Conference Call and Webcast
RICHMOND, Calif., Feb. 20, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that the company will release its fourth quarter and full year 2017 financial results before the market opens on Thursday, February 22, 2018. The press release will be followed by a conference call at 8:00 a.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review its financial results and provide a business update.
Feb 13, 2018 07:00 am ET
Sangamo Presents Oncology Genome Editing Capabilities at Keystone Symposium on Emerging Cellular Therapies
RICHMOND, Calif., Feb. 13, 2018 /PRNewswire/ -- Sangamo Therapeutics (Nasdaq: SGMO) yesterday presented preclinical data demonstrating the Company's engineering capabilities in T cell genome editing using zinc finger nucleases (ZFNs). Sangamo Scientist Sumiti Jain, Ph.D. delivered the presentation, "Dual Knock-Out of Endogenous T-Cell Receptor and Human Leukocyte Antigen and Site-Specific Insertion of a CD19-CAR: Implications for Allogeneic T Cell Therapy," at the Keystone Symposium on Emerging Cellular Therapies: T Cells and Beyond.
Feb 12, 2018 03:01 pm ET
Sangamo Therapeutics Announces Appointment Of Heather D. Turner As Senior Vice President And General Counsel
RICHMOND, Calif., Feb. 12, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced the appointment of Heather D. Turner as senior vice president and general counsel, effective immediately. Ms. Turner will oversee all legal matters for the Company and will report to Sangamo's chief executive officer.
Feb 07, 2018 06:30 am ET
Case Western Reserve and Sangamo Therapeutics Announce $11 Million NIH Grant for Study of Gene-Edited T Cells for Viral Eradication of HIV
CLEVELAND and RICHMOND, Calif., Feb. 7, 2018 /PRNewswire/ -- Case Western Reserve University and Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced the award of an $11 million grant from the National Institutes of Health for a planned study of gene-edited T cells designed to eradicate persistent HIV infection in patients receiving anti-retroviral therapy, a combination of medicines that slows the rate at which HIV replicates.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.